Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLSGet Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays lowered their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th.

Check Out Our Latest Analysis on CLLS

Cellectis Price Performance

Shares of NASDAQ:CLLS opened at $1.64 on Thursday. Cellectis has a twelve month low of $1.41 and a twelve month high of $3.38. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a market cap of $91.16 million, a PE ratio of -1.26 and a beta of 3.08. The company’s 50 day moving average is $1.85 and its 200 day moving average is $2.01.

Cellectis (NASDAQ:CLLSGet Free Report) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. During the same quarter in the previous year, the company earned ($0.31) EPS. On average, sell-side analysts forecast that Cellectis will post -0.46 EPS for the current year.

Institutional Trading of Cellectis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in shares of Cellectis during the 2nd quarter worth about $29,000. First Affirmative Financial Network purchased a new position in shares of Cellectis in the 3rd quarter valued at about $45,000. Finally, Long Focus Capital Management LLC raised its holdings in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the period. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Further Reading

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.